Inhibikase Therapeutics Reports Q2 2026 Financial Results

What Happened
Inhibikase Therapeutics, Inc. (IKT) announced its financial results for the quarter ended June 30, 2026 in an 8‑K filed on August 11, 2026. The company furnished a press release detailing the results and corporate updates as Exhibit 99.1 to the Form 8‑K. The filing states the information is being furnished (not “filed”) for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Announcement date: August 11, 2026.
• Reporting period: quarter ended June 30, 2026.
• Press release: furnished as Exhibit 99.1 to the Current Report on Form 8‑K.
• Technical filing note: the cover page interactive XBRL file (104) is included; the furnished materials are not deemed “filed” under the Exchange Act.

Why It Matters
This 8‑K provides the company’s most recent quarterly results and corporate updates that investors use to assess performance (earnings, revenue, cash position, and operational progress). Investors should review the furnished press release (Exhibit 99.1) for the specific financial metrics and any company commentary or guidance; the Form 8‑K itself confirms the release and filing status but does not include line‑item financial detail in the filing cover text.